IDEXX Laboratories, Inc. (IDXX) Position Trimmed by Arrowstreet Capital Limited Partnership

Arrowstreet Capital Limited Partnership trimmed its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4.3% during the fourth quarter, Holdings Channel reports. The institutional investor owned 1,254,413 shares of the company’s stock after selling 57,047 shares during the period. Arrowstreet Capital Limited Partnership’s holdings in IDEXX Laboratories were worth $196,165,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Advisors Capital Management LLC acquired a new position in IDEXX Laboratories during the third quarter worth $262,000. Wells Fargo & Company MN increased its holdings in IDEXX Laboratories by 7.8% during the third quarter. Wells Fargo & Company MN now owns 338,968 shares of the company’s stock worth $52,706,000 after buying an additional 24,510 shares during the last quarter. Cabot Wealth Management Inc. acquired a new position in IDEXX Laboratories during the third quarter worth $1,359,000. Macquarie Group Ltd. increased its holdings in IDEXX Laboratories by 7.0% during the third quarter. Macquarie Group Ltd. now owns 38,000 shares of the company’s stock worth $5,909,000 after buying an additional 2,500 shares during the last quarter. Finally, Atlantic Trust Group LLC acquired a new position in IDEXX Laboratories during the third quarter worth $65,381,000. Institutional investors and hedge funds own 86.50% of the company’s stock.

IDXX has been the subject of a number of research analyst reports. Zacks Investment Research raised shares of IDEXX Laboratories from a “hold” rating to a “strong-buy” rating and set a $214.00 price objective for the company in a research report on Monday, February 5th. BidaskClub cut shares of IDEXX Laboratories from a “hold” rating to a “sell” rating in a research report on Saturday, December 16th. Bank of America lifted their price objective on shares of IDEXX Laboratories from $200.00 to $220.00 and gave the stock a “buy” rating in a research report on Friday, February 2nd. Piper Jaffray Companies lifted their price objective on shares of IDEXX Laboratories to $211.00 and gave the stock an “overweight” rating in a research report on Thursday, February 1st. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $185.00 price objective on shares of IDEXX Laboratories in a research report on Tuesday, October 24th. One investment analyst has rated the stock with a sell rating, six have given a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $194.00.

In other IDEXX Laboratories news, Director Lawrence D. Kingsley bought 1,000 shares of IDEXX Laboratories stock in a transaction dated Wednesday, February 14th. The stock was bought at an average price of $178.05 per share, with a total value of $178,050.00. Following the completion of the transaction, the director now owns 4,558 shares in the company, valued at approximately $811,551.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Giovani Twigge sold 2,000 shares of the business’s stock in a transaction dated Thursday, November 30th. The shares were sold at an average price of $156.07, for a total transaction of $312,140.00. The disclosure for this sale can be found here. In the last three months, insiders sold 86,762 shares of company stock valued at $15,202,484. 2.77% of the stock is currently owned by company insiders.

IDEXX Laboratories, Inc. (NASDAQ IDXX) opened at $182.48 on Monday. The company has a current ratio of 0.97, a quick ratio of 0.80 and a debt-to-equity ratio of -11.26. IDEXX Laboratories, Inc. has a 52-week low of $141.02 and a 52-week high of $198.73. The company has a market cap of $15,920.00, a price-to-earnings ratio of 55.63, a price-to-earnings-growth ratio of 2.24 and a beta of 0.58.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Thursday, February 1st. The company reported $0.77 EPS for the quarter, topping the Zacks’ consensus estimate of $0.73 by $0.04. IDEXX Laboratories had a net margin of 13.36% and a negative return on equity of 432.19%. The firm had revenue of $506.00 million during the quarter, compared to analysts’ expectations of $490.51 million. During the same period in the previous year, the business posted $0.58 earnings per share. The company’s revenue for the quarter was up 14.2% compared to the same quarter last year. equities analysts predict that IDEXX Laboratories, Inc. will post 4.09 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “IDEXX Laboratories, Inc. (IDXX) Position Trimmed by Arrowstreet Capital Limited Partnership” was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this news story on another publication, it was stolen and reposted in violation of United States & international copyright laws. The original version of this news story can be accessed at https://stocknewstimes.com/2018/02/19/idexx-laboratories-inc-idxx-position-trimmed-by-arrowstreet-capital-limited-partnership.html.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply